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Drug resistance mutations in the nucleotide binding pocket of
human immunodeficiency virus type 1 reverse transcriptase
differentially affect the phosphorolysis-dependent primer
unblocking activity in the presence of stavudine and zidovudine
and its inhibition by efavirenz
Abstract
Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) derivatives with D113E,
Y115F, F116Y, Q151E/N, and M184V mutations were studied for their phosphorolysis-mediated
resistance to the nucleoside RT inhibitors (NRTIs) zidovudine and stavudine and for their inhibition by
the nonnucleoside analogs (NNRTIs) efavirenz and nevirapine. The results presented here indicate that
these single amino acid substitutions within the nucleotide binding pocket of the viral RT can
independently affect different enzymatic properties, such as catalytic efficiency, drug binding, and
phosphorolytic activity. Moreover, small local alterations of the physicochemical properties of the
microenvironment around the active site can have profound effects on some NRTIs while hardly
affecting other ones. In conclusion, even though different mutations within the nucleotide binding
pocket of HIV-1 RT can result in a common phenotype (i.e., drug resistance), the molecular
mechanisms underlying this phenotype can be very different. Moreover, the same mutation can give rise
to different phenotypes depending on the nature of the substrates and/or inhibitors.
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Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) derivatives with D113E, Y115F,
F116Y, Q151E/N, and M184V mutations were studied for their phosphorolysis-mediated resistance to the
nucleoside RT inhibitors (NRTIs) zidovudine and stavudine and for their inhibition by the nonnucleoside
analogs (NNRTIs) efavirenz and nevirapine. The results presented here indicate that these single amino acid
substitutions within the nucleotide binding pocket of the viral RT can independently affect different enzymatic
properties, such as catalytic efficiency, drug binding, and phosphorolytic activity. Moreover, small local
alterations of the physicochemical properties of the microenvironment around the active site can have pro-
found effects on some NRTIs while hardly affecting other ones. In conclusion, even though different mutations
within the nucleotide binding pocket of HIV-1 RT can result in a common phenotype (i.e., drug resistance), the
molecular mechanisms underlying this phenotype can be very different. Moreover, the same mutation can give
rise to different phenotypes depending on the nature of the substrates and/or inhibitors.
Current therapy for human immunodeficiency virus (HIV)-
infected patients is based on a combination of multiple nucle-
oside reverse transcriptase inhibitors (NRTIs), nonnucleoside
inhibitors (NNRTIs), and protease inhibitors (PIs) (22, 28). As
a consequence, HIV in many of these patients has developed
mutations that confer resistance to the NRTIs (14). Mutations
in RT may confer resistance either by decreasing the incorpo-
ration of inhibitors or by increasing the removal of inhibitors
after they are incorporated (23, 24). In fact, HIV type 1
(HIV-1) RT can remove a chain-terminating inhibitor after it
has been incorporated through a pyrophosphorolysis mecha-
nism, the reverse reaction of nucleotide polymerization (15,
16). In this process, RT in complex with a dideoxynucleoside
monophosphate-terminated primer-template binds pyrophos-
phate (PPi) or ATP and catalyzes the removal of the chain-
terminating dideoxynucleoside monophosphate from the
primer, resulting in an unblocked DNA chain. It has been
shown that HIV-1 mutant RTs with common thymidine analog
resistance mutations have increased rates of thymidine analog
removal in the presence of physiological concentrations of
ATP (11, 17). This suggests that the effects of certain NRTI
resistance mutations on this mechanism can contribute to the
reduced drug susceptibility of the mutated HIV (5, 21). A
kinetic analysis of the removal of zidovudine monophosphate
(AZTMP) and stavudine monophosphate (d4TMP) also
showed that for both thymidine analogues, the rate of PPi-
dependent removal by wild-type RT was 40- to 60-fold faster
than the rate of ATP-mediated removal under estimated phys-
iological concentrations of PPi or ATP. On the other hand, the
rate of ATP-dependent removal was enhanced as much as
10-fold by thymidine analog resistance mutations (19). An ad-
ditional observation was that the next correct incoming nucle-
otide can inhibit the ATP-dependent chain terminator removal
of d4TMP by both wild-type and drug-resistant RT, whereas the
PPi-mediated removal of d4TMP by mutant RT showed a de-
creased level of inhibition by the next correct nucleotide (19).
Thus, a decreased level of inhibition by the next correct nucleo-
tide may allow mutant RT to utilize the more rapid process of
PPi-mediated removal to enhance resistance as well as to mini-
mize the inhibition of ATP-mediated removal in a cellular envi-
ronment in which the next deoxynucleotide is present.
An examination of the three-dimensional structure of the
HIV-1 RT-DNA-deoxynucleoside triphosphate (dNTP) ter-
nary complex (8) showed that several amino acid residues are
involved in the formation of the dNTP-binding pocket in the
ternary complex. These include residues which are also mu-
tated in response to NRTI-based chemotherapy, such as D113,
Y115, F116, Q151, and M184. Mutations involving these amino
acid residues in the dNTP-binding pocket may alter the size
and shape of this pocket, thus resulting in alterations of dNTP
selectivity, polymerization, and pyrophosphorolysis (7, 27).
As mentioned above, in the setting of highly active antiret-
roviral therapy, NRTIs are used in combination with NNRTIs.
The latter class of inhibitors includes a large number of struc-
turally dissimilar hydrophobic compounds that bind to a site on
the RT palm subdomain adjacent to but distinct from the poly-
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merase active site (6). Because both groups of inhibitors bind to
different sites on RT in a nonexclusive manner, combinations of
nucleoside analogs and nonnucleoside inhibitors may have a syn-
ergistic inhibitory effect on HIV-1 RT. Indeed, synergistic inhibi-
tion has been reported for many combinations of nucleoside and
nonnucleoside RT inhibitors both in enzymatic tests (13) and in
cell culture viral replication assays (10). The molecular basis for
this synergistic effect has recently been elucidated by several stud-
ies, which showed that many NNRTIs have the ability to inhibit
the phosphorolytic removal of a chain-terminating nucleotide an-
alog such as AZTMP or d4TMP (2, 18). Aside from their rele-
vance for the development of better therapeutic protocols, these
results suggested that the binding of NNRTIs to the viral RT can
influence the shape and/or geometry of the dNTP-binding pocket
(12, 26), thus affecting both polymerization and phosphorolytic
activities.
In an effort to understand the contribution of residues in the
dNTP-binding pocket to the mechanism of phosphorolysis-
mediated resistance to NRTIs and to its inhibition by NNRTIs,
we studied RT derivatives with D113E, Y115F, F116Y,
Q151E/N, and M184V mutations for their involvement in the
process of PPi-dependent removal of the chain-terminating
thymidine analogs AZTMP and d4TMP as well as for their
sensitivities to NNRTI inhibition.
MATERIALS AND METHODS
Chemicals. [3H]dTTP (40 Ci/mmol), [-32P]ATP (3,000 Ci/mmol), and AZT
triphosphate were purchased from Amersham Biosciences. Poly(rA), oligo(dT), 66-
and 24-mer oligodeoxynucleotides, and unlabeled dNTPs were purchased from
Roche Molecular Biochemicals. Whatman was the supplier of GF/C filters. All other
reagents were of analytical grade and were purchased from Merck or Fluka.
Nucleic acid substrates. The homopolymer poly(rA) (Pharmacia) was mixed
with the oligomer oligo(dT)12–18 (Pharmacia) at a nucleotide weight ratio of 10:1
in 20 mM Tris-HCl (pH 8.0) containing 20 mM KCl and 1 mM EDTA, heated
at 65°C for 5 min, and then slowly cooled to room temperature. The template
oligonucleotide d66-mer was mixed with the complementary primer d24-mer at
an equimolar ratio in 20 mM Tris-HCl (pH 8.0) containing 20 mM KCl and 1
mM EDTA, heated at 85°C for 3 min, incubated for 15 min at 37°C, and finally
slowly cooled down to room temperature. Before annealing, the 24-mer primer
was 5 end labeled with T4 polynucleotide kinase (Roche Molecular Biochemi-
cals) and [-32P]ATP according to the manufacturer’s protocol.
Expression and purification of recombinant HIV-1 RT forms. pUC12N/
p66(His)/p51 coexpression vectors with wild-type or mutant forms of HIV-1 RT
p66 (3) were kindly provided by S. H. Hughes (NCI-Frederick Cancer Research
and Development Center) and were purified in two steps. Escherichia coli strain
JM109(DE3) cultures harboring the corresponding expression plasmids were
grown at 37°C in 1 liter of Luria broth to an A600 of 0.6. Isopropylthiogalactoside
was added to a final concentration of 1 mM, and growth was continued for 4 h.
The cells were harvested by centrifugation, resuspended in 10 ml of buffer A (40
mM Tris [pH 8.0], 0.5 M NaCl, 1 mM phenylmethylsulfonyl fluoride [PMSF]),
and subjected to lysis in a French press. The mixture was cleared by centrifuga-
tion at 30,000  g for 30 min. The supernatant was loaded on a 1-ml HiTrap
chelating column complexed with Co2 ions and equilibrated with buffer A. The
enzyme was eluted from the column with a 0 to 0.5 M imidazole-HCl gradient in
buffer A. Pooled fractions were dialyzed against buffer B (50 mM Tris-HCl [pH
7.5], 50 mM NaCl, 1 mM 2-mercaptoethanol, 0.4 mM PMSF, 10% [vol/vol]
glycerol) and then loaded onto a Mono S column (Pharmacia) equilibrated in
buffer B. The HIV-1 RT proteins were eluted from the column with a 50 to 500
mM NaCl gradient in buffer B. Pooled fractions were dialyzed against a buffer
containing 50 mM Tris-HCl (pH 7.5), 20% (vol/vol) glycerol, 1 mM EDTA, 1
mM dithiothreitol (DTT), and 0.4 mM PMSF. All enzymes were purified to
95% purity and had the following specific activities on poly(rA)-oligo(dT):
HIV-1 p66(His)/p51, 75,670 U/mg; p66(D113E)/p51, 16,690 U/mg; p66(Y115F)/
p51, 96,415 U/mg; p66(F116Y)/p51, 62,760 U/mg; p66(Q151E)/p51, 26,760
U/mg; p66(Q151N)/p51, 25,770 U/mg; and p66(M184V)/p51, 79,050 U/mg. One unit
of DNA polymerase activity corresponds to the incorporation of 1 nmol of de-
oxynucleoside monophosphate into acid-precipitable material in 60 min at 37°C.
HIV-1 RT RNA-dependent DNA polymerase activity assay. RNA-dependent
DNA polymerase activity was assayed as follows. Each final reaction volume of
25 l contained reaction buffer (50 mM Tris-HCl [pH 7.5], 1 mM DTT, 0.2 mg
of bovine serum albumin/ml, 4% glycerol), 10 mM MgCl2, 0.5 g of poly(rA)-
oligo(dT)10:1 (0.3 M 3-OH ends), 10 M [3H]dTTP (1 Ci/mmol), and 2 to 4
nM RT. The reactions were incubated at 37°C for the indicated times. Twenty-
microliter aliquots were then spotted onto glass fiber GF/C filters, which were
immediately immersed in 5% ice-cold trichloroacetic acid. The filters were
washed twice in 5% ice-cold trichloroacetic acid and once in ethanol for 5 min
and then dried, and acid-precipitable radioactivities were quantitated by scintil-
lation counting. When the 5-32P-labeled d24-d66-mer template was used, the
reaction volume was 10 l and contained 0.05 M (3-OH ends) DNA template
and the enzymes and nucleotides indicated in the figure legends. After incuba-
tion at 37°C, the products of the reaction were separated in a 7 M urea–14%
polyacrylamide sequencing gel. Quantification of the products was performed by
scanning the gel with a Molecular Dynamics PhosphorImager and integrating the
data with the program ImageQuant.
Steady-state kinetic measurements. Reactions were performed under the con-
ditions described for the HIV-1 RT RNA-dependent DNA polymerase activity
assay. The time-dependent incorporation of radioactive dTTP into poly(rA)-
oligo(dT) at different substrate concentrations was monitored by removing 25-l
aliquots at different time points. Initial velocities of the reaction, as determined
by linear regression analyses of the data, were then plotted against the corre-
sponding substrate concentrations.
When the 5-32P-labeled d24-d66-mer template was used, initial velocities
after 10 min of incubation at 37°C in the presence of different substrate concen-
trations were calculated from the integrated gel band intensities (see below).
The data were analyzed by non-least-square computer fitting to the Michaelis-
Menten equation in the form v  Vmax/(1  Km/[S]), where Vmax  kcatE0.
The values of integrated gel band intensities depending on the PPi concen-
trations were fitted to the following equation: I*T/IT  1  Vmax[PPi]/(Kd 
[PPi]), where T is the target site, or the template position of interest, and I*T is
the sum of the integrated intensities at positions T, T  1. . .T  n.
For determinations of the Km and Vmax values, an interval of substrate con-
centrations from 0.2 to 10 Km was used.
Inhibition assays. Reactions were performed under the conditions described
for the HIV-1 RT RNA-dependent DNA polymerase activity assay. The incor-
poration of radioactive dTTP into poly(rA)-oligo(dT) at different concentrations
of dTTP was monitored in the presence of increasing fixed amounts of the
inhibitor being tested. The data were analyzed by non-least-square computer
fitting to the equation for competitive (AZTTP and d4TTP) or noncompetitive
(efavirenz and nevirapine) inhibition. For Ki determinations, an interval of in-
hibitor concentrations between 0.2 and 5 Ki was used.
For determinations of the variation in Kis for AZTTP in the presence of PPi,
increasing concentrations of AZTTP were titrated in standard inhibition assays in
the absence or presence of a fixed concentration of PPi, as indicated in the text.
Determination of kinetic parameters for efavirenz binding and dissociation.
An experiment to determine the kinetic parameters for efavirenz binding and
dissociation was performed as follows. HIV-1 RT (20 to 40 nM), either wild type
or mutated, was incubated for 2 min at 37°C in a final volume of 4 l in the
presence of 15 nM 3-OH ends, reaction buffer, and 10 mM MgCl2. Efavirenz
was then added to a final volume of 5 l. Then, 145 l of a mix containing buffer
A, 10 mM MgCl2, and 10 M [3H]dTTP (1 Ci/mmol) was added at different time
points. After an additional 10 min of incubation at 37°C, 50-l aliquots were
spotted onto GF/C filters and acid-precipitable radioactivities were measured as
described for the HIV-1 RT RNA-dependent DNA polymerase activity assay.
The fraction of enzyme that was in complex with the inhibitor at equilibrium was
estimated by use of the following equation: [E:I]/[E]0  {1  1/(1[I]/Ki)}. This
fraction was kept at 90%. The samples were diluted by a factor of 30 in order
to prevent both reinitiation by the enzyme and rebinding of the inhibitor after
dissociation during the incorporation step. The amount of dTTP incorporated
into poly(rA)-oligo(dT) at the zero time point (v0, uninhibited reaction) was pro-
portional to the amount of RT present at the beginning of the reaction ([E]0),
whereas the incorporation measured at subsequent time points (vt) was directly
proportional to the amount of uninhibited RT ([E]t  [E]0  [E:I]t). Thus, the
difference (v0 vt) gives an estimate of the [E:I] complex formed at each time point,
since (v0  vt)  ([E]0  [E]0  [E:I]t). Parallel reactions were run for 10 min at
37°C, with enzyme, inhibitor, and substrates present at the same concentrations as in
the diluted mixture, but without any preincubation. Incorporation values were typ-
ically between 2 and 5% of those for the uninhibited reaction (zero time point).
These values were subtracted as background values. The kapp values were deter-
mined by fitting the experimental data to the following single-exponential equation:
(v0  vt)/v0  A[1  ekappt)], where A is a constant and t is time.
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The koff and kon values were then derived from the relationships kapp  kon(Ki
 [I]) and Ki  koff/kon (25).
RESULTS
HIV-1 RTs carrying mutations in the nucleotide binding
pocket show different sensitivities to AZTTP, d4TTP, PPi, ne-
virapine, and efavirenz. Recombinant HIV-1 RTs, either wild
type or carrying single amino acid mutations in the nucleotide
binding pocket (Fig. 1), were tested for their affinities for
dTTP, AZTTP (AZT triphosphate, the active form of the
clinically approved drug zidovudine), PPi, and the NNRTIs
efavirenz and nevirapine. The results are summarized in Table
1. The Q151N, Q151E, and D113E mutants showed a 2.5-, 3-,
and 5-fold reduction, respectively, of the kcat values for dTTP
incorporation with respect to the wild type. Moreover, all of
the mutants tested showed a decrease in apparent affinity for
the dTTP substrate. The most affected was the Q151E mutant,
with an 11-fold increase in its apparent Km value. Similarly, all
of the mutants showed a decreased sensitivity to inhibition by
AZTTP and PPi, with the Q151E mutant being the most re-
sistant (7.7-fold increase in the Ki value for AZTTP and 3.5-
fold increase in the Ki for PPi). Interestingly, the conservative
mutation Q151N at the same position did not show major
effects on the affinity for dTTP or the inhibition by PPi, but it
caused a significant decrease (5.5-fold) in the inhibition by
AZTTP. On the other hand, the Y115F mutation, which
strongly affected the affinity of RT for the dTTP substrate, had
only a small effect on inhibition by AZTTP and PPi (2.6- and
1.6-fold increases in Ki values, respectively). The D113E mu-
tant, however, showed a close correlation between the de-
crease in the affinity for dTTP (3.3-fold) and the resistance to
PPi inhibition (2.3-fold), but it did not show a significant effect
FIG. 1. HIV-1 RT mutations analyzed in this study. The crystal structure of the HIV-1 RT heterodimer in complex with DNA and TTP (PDB entry
1RTD) is shown in the top left corner. The purple circle indicates the region to which the mutations analyzed in the present study (blue) are localized,
together with the bound TTP (red). This region is magnified in the bottom right corner, where only the mutated residues and TTP are shown for greater
clarity. The picture was generated with the program SwissPDBViewer 3.5 and further enhanced with Adobe Photoshop CS 8.0.
TABLE 1. Binding affinities of wild-type HIV-1 RT and mutant RTs for dTTP, AZTTP, d4TTP, PPi, efavirenz, and nevirapinea
RT mutation
Parameters for TTP Ki (in indicated units) of enzyme for drug
Km (M) kcat (s1)
AZTTP
(nM)
D4TTP
(nM)
PPi
(mM) EFV (M) NVP (M)
Wild type 3.9 	 0.2 0.15 	 0.03 45 48 0.185 0.06 	 0.005 0.35 	 0.03
D113E 13.1 	 0.3 0.03 	 0.001 75 ND 0.425 0.04 	 0.003 ND
Y115F 4.5 	 0.5 0.13 	 0.02 120 43.5 0.290 ND ND
F116Y 24.5 	 3 0.14 	 0.03 ND ND ND 0.04 	 0.005 ND
Q151N 8.9 	 1 0.06 	 0.004 250 170 0.316 0.02 	 0.001 0.08 	 0.003
Q151E 44.5 	 5 0.05 	 0.005 350 750 0.653 0.03 	 0.001 ND
M184V 31.3 	 4 0.16 	 0.02 ND ND ND 0.03 	 0.004 ND
a EFV, efavirenz; NVP, nevirapine. Data are means 	 standard deviations for three independent measurements. ND, not done.
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on the inhibition by AZTTP (only a 1.6-fold increase in the Ki
value with respect to the wild type). When they were tested for
sensitivity to the NNRTI efavirenz (Table 1), most of the
mutated enzymes displayed sensitivities comparable to that of
the wild type, with the relevant exception of the Q151E and
Q151N mutants, which had a two- and threefold increase,
respectively, in sensitivity to efavirenz inhibition with respect
to the wild-type enzyme.
In order to verify whether the observed effects of the Y115F
and Q151E/N mutations were specific for the inhibitors tested,
we compared the sensitivities of these mutants to d4TTP (the
active form of the thymidine analog stavudine) and to the
clinically used NNRTI nevirapine with those of wild-type RT.
The results are listed in Table 1. Inhibition of the Y115F
mutant by d4TTP was not significantly affected with respect to
the wild-type enzyme. Both the Q151E and Q151N mutants,
on the other hand, showed significant resistance to d4TTP
inhibition, consistent with the well-known multidrug resistance
phenotype of Q151 mutant viruses. Remarkably, the Q151N
mutant enzyme showed a hypersensitivity to nevirapine inhibi-
tion (fourfold) similar to that observed with efavirenz (three-
fold). These results indicate that even if all of the mutated
residues contribute to the nucleotide binding pocket of HIV-1
RT, they can differentially affect the enzyme’s sensitivity to
both NRTIs and NNRTIs.
Mutations in the nucleotide binding pocket of HIV-1 RT
affect binding and dissociation of the NNRTI efavirenz. Next,
the actual binding and dissociation rates of efavirenz were
determined for the recombinant HIV-1 RTs, either wild type
or carrying the single amino acid mutations D113E, Q151E/N,
and M184V, and the derived kinetic constants are summarized
in Table 2 (see Materials and Methods). The hypersensitivity
of the Q151N mutant could be explained in terms of an in-
creased association rate (5.1-fold higher than that of the wild
type) of the drug with the mutated enzyme. All of the other
mutants showed only minor variations with respect to the wild
type according to their similar Ki values, as reported in Table 1. It
is interesting, however, that the slight increase in the sensitivities
of the D113E and Q151E mutants to efavirenz was due to higher
inhibitor association rates, whereas the same effect noted for the
M184V mutant could be explained by a slightly lower efavirenz
dissociation rate. These results indicate that different amino acid
substitutions in the NRTI binding site can affect both the associ-
ation and dissociation rates of NNRTIs, suggesting that there is
cross talk between the nucleotide binding site and the NNRTI
binding pocket in HIV-1 RT.
Mutations in the nucleotide binding pocket of HIV-1 RT
affect the phosphorolytic unblocking of AZTMP-terminated
primers. As reported in Tables 1 and 2, some of the mutations
analyzed in this study affected the sensitivity of HIV-1 RT to
both PPi and efavirenz. Thus, we asked whether these muta-
tions affected both the primer unblocking activity of RT and its
sensitivity to efavirenz inhibition. In preliminary experiments,
the effects of physiological concentrations of PPi on the po-
tency of inhibition of HIV-1 RT by AZTTP were tested. An
inhibition curve obtained in a typical experiment with wild-type
HIV-1 RT is shown in Fig. 2. Similar experiments were per-
formed with the other enzymes, and the results are summa-
rized in Table 3. The presence of 0.2 mM PPi in the reaction
significantly decreased (20-fold) the inhibition of wild-type RT
by AZTTP, suggesting that AZTMP-terminated primers were
efficiently unblocked. The level of reduction of AZTTP inhi-
bition by PPi was different for each RT enzyme tested, in the
following order: D113E (25.3-fold)  wild type (20-fold) 
Y115F (7.5-fold)  Q151N (3.8-fold)  Q151E (1.8-fold).
Interestingly, there was a clear correlation between a decrease
in affinity for PPi and a lower efficiency of primer unblocking
for the Q151N/E mutants, but not for the D113E mutant
(Table 1), indicating that reduced PPi binding was not the sole
determinant of the decrease in primer unblocking activity. As
shown in Table 3, when AZTTP inhibition was studied in the
presence of both PPi and efavirenz, all of the enzymes tested
regained full sensitivity to AZTTP (i.e., at the same or near the
levels seen in the absence of PPi), indicating that primer un-
blocking was inhibited by efavirenz, with the only exception
being the Q151E mutant, which showed the same Ki for
FIG. 2. Effect of PPi on inhibition of wild-type HIV-1 RT by
AZTTP. Experiments were performed as described in Materials and
Methods with wild-type HIV-1 RT in the absence (circles) or presence
(triangles) of PPi and in the presence of increasing concentrations of
AZTTP (0.05, 0.1, 0.2, 0.3, and 0.5 M). Each point represents the
mean value of three independent determinations. Error bars indicate
standard deviations.
TABLE 2. Kinetic parameters for efavirenz binding to and dissociation from HIV-1 wild-type RT and mutant RTsa
RT mutation Ki (M) kon (M1 s1) koff (s1)
Wild type 0.06 	 0.004 1.76  103 	 0.2  103 1.15  104 	 0.5  104
D113E 0.04 	 0.003 3.3  103 	 0.5  103 1.37  104 	 0.6  104
Q151E 0.03 	 0.003 3.7  103 	 0.3  103 1.2  104 	 0.2  104
Q151N 0.02 	 0.001 9.1  103 	 0.5  103 1.2  104 	 0.1  104
M184V 0.04 	 0.003 1.9  103 	 0.5  103 0.65  104 	 0.5  104
a Derived from the kapp values calculated from the experiments shown in Fig. 1. Data are means 	 standard deviations for three independent measurements.
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AZTTP in the presence of PPi alone or in combination with
efavirenz. This was not due to reduced binding of the NNRTI
to this mutant, since the Q151E RT bound efavirenz as well as,
or even better than, the wild type (Tables 1 and 2; Fig. 1).
These results suggest that mutations in the nucleotide binding
pocket of HIV-1 RT affect both the phosphorolysis-dependent
primer unblocking activity and its inhibition by efavirenz.
The efficiency of AZTMP removal by HIV-1 RT is affected by
the Q151E/N mutations in the enzyme’s nucleotide binding
pocket. The data presented in Table 3 suggest that mutations
at position Q151 of HIV-1 RT significantly affect the enzyme’s
ability to remove a chain-terminating AZTMP residue in the
presence of PPi. To directly investigate this, we measured the
phosphorolysis-dependent primer unblocking activity of wild-
type HIV-1 RT and the Q151E/N mutants on the heteropoly-
meric DNA primer-template d24-d66-mer, whose sequence
corresponds to nucleotides 1006 to 1071 (codons 169 to 190 of
the RT coding sequence) of the HIV-1 pol gene (HXB2 iso-
late). To this aim, we employed a “running start” assay, in
which the chain-terminating nucleoside analogue was comple-
mentary to position 2 of the template strand. The RT to be
studied was incubated for 10 min in the presence of the first
encoded nucleotide (dCTP in our case) and the nucleoside
analog of interest (AZTTP in this case). This resulted in the
generation of a chain-terminated 2 product. Increasing
amounts of PPi were then added, and the incubation was
continued for an additional 15 min before it was stopped and
the products were resolved by denaturing polyacrylamide gel
electrophoresis. Since both dCTP and AZTTP were present in
the reaction together with PPi, the steady-state rate of phos-
phorolysis measured under these conditions represented the
net rate at which equilibrium was reached among the forward
rates of dCTP and AZTTP incorporation and the backward
rates of dCMP and AZTMP removal. Thus, this assay should
more closely reflect the conditions encountered by HIV-1 RT
during DNA synthesis in vivo. Moreover, it closely mimics the
reaction conditions used for the determination of the Ki values
listed in Table 3. As shown in Fig. 3A, when wild-type RT was
incubated in the presence of dCTP and AZTTP, synthesis
terminated at position 2, as expected from the template
sequence (lane 1). The subsequent addition of increasing
amounts of PPi (lanes 2 to 7) caused a decrease in the amounts
of incorporated products, which completely disappeared in the
presence of 2 mM PPi (lane 6). When the same experiment was
repeated with the Q151E mutant (Fig. 3C), the 2 products
were still detectable in the presence of 10 mM PPi (lane 8),
indicating a lower primer unblocking activity for this mutant and
agreeing with the data shown in Table 3. On the other hand, the
Q151N mutant (Fig. 3E) showed nearly the same efficiency of
primer unblocking as the wild type, with only a slightly larger
amount of 2 products detectable at 0.2, 0.5, and 1 mM PPi
(compare Fig. 1C, lanes 3 to 5, with Fig. 1A, lanes 3 to 5).
Quantification of the bands allowed the determination of the
apparent Kd values for PPi and of the apparent kcat for the pyro-
phosphorolytic removal of AZTMP, which are reported in Table
4. As shown in the table, the Q151N mutant had nearly the same
kcat as the wild-type enzyme, whereas the Kd for PPi was threefold
higher for the mutant, suggesting that the Q151N mutation mod-
erately reduced the affinity of PPi binding (also see Table 1). On
the other hand, the Q151E mutant showed an approximately
3-fold reduction in the kcat value with respect to the wild type and
a 7.7-fold increase in the Kd for PPi, indicating that the Q151E
substitution affected both the affinity for PPi and the rate of
pyrophosphorolysis of AZTMP.
It is interesting that the apparent Kd values for PPi listed in
Table 4 are different from the values reported in Table 1. This
is due to the fact that the values in Table 1 reflect the apparent
FIG. 3. PPi-dependent removal of a chain-terminating AZTMP
residue by wild-type HIV-1 RT and the Q151E and Q151N mutants
and its inhibition by efavirenz. (A) Reactions were carried out as
described in Materials and Methods, with 40 nM wild-type RT, 2 M
dCTP, and 0.2 M AZTTP and in the absence (lane 1) or presence
(lanes 2 to 7) of increasing amounts of PPi. M, 5-labeled 24-mer
oligonucleotide marker. The template sequence is shown on the right side
of the panel. The removal of AZTMP is indicated by a decrease in 2
products which is dependent on the PPi concentration. (B) Same condi-
tions as those for panel A, but with the presence of 0.3 M efavirenz in
lanes 2 to 7. (C) Reactions were carried out as described in Materials and
Methods, with 60 nM Q151E RT, 2 M dCTP, and 2 M AZTTP and in
the absence (lane 1) or presence (lanes 2 to 8) of increasing amounts of
PPi. M, 5-labeled 24-mer oligonucleotide marker. The template se-
quence is shown on the right side of the panel. The removal of AZTMP
is indicated by a decrease in 2 products which is dependent on the PPi
concentration. (D) Same conditions as those for panel C, but with the
presence of 0.3 M efavirenz in lanes 2 to 8. (E) Reactions were carried
out as described in Materials and Methods, with 60 nM Q151N RT, 2 M
dCTP, and 2 M AZTTP and in the absence (lane 1) or presence (lanes
2 to 8) of increasing amounts of PPi. M, 5-labeled 24-mer oligonucleotide
marker. The template sequence is shown on the right side of the panel.
The removal of AZTMP is indicated by a decrease in 2 products which
is dependent on the PPi concentration.
TABLE 3. Effects of PPi and efavirenz on inhibition of HIV-1 wild-
type RT and mutant RTs by AZTTP
RT
mutation
Ki (M) for AZTTP
a
No PPi, no EFV  0.3 mM PPi Foldreduction
 0.3 mM
PPi and EFV
Fold
reduction
Wild type 0.045 	 0.004 0.9 	 0.08 20 0.1 	 0.02 2.2
D113E 0.075 	 0.006 1.9 	 0.1 25.3 0.2 	 0.02 2.6
Y115F 0.12 	 0.02 0.9 	 0.1 7.5 0.11 	 0.008 0.9
Q151E 0.25 	 0.02 0.45 	 0.04 1.8 0.43 	 0.04 1.7
Q151N 0.35 	 0.04 0.95 	 0.08 3.8 0.3 	 0.04 0.8
a Data are means 	 standard deviations for three independent measurements.
EFV, efavirenz.
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affinities of PPi binding to RT during the phosphorolytic re-
moval of incorporated dTMP, whereas the values in Table 4
refer to the removal of AZTMP (and d4TMP). This observa-
tion suggests that the apparent affinity of RT for PPi is influ-
enced by the nature of the nucleotide to be removed.
The Q151E mutation in the nucleotide binding pocket of
HIV-1 RT affects inhibition by efavirenz of the phosphorolysis-
dependent removal of AZTMP. The data reported in Table 3
suggest that efavirenz does not affect the ability of the Q151E
mutant to remove a chain-terminating AZTMP residue. In
order to directly verify this, we added increasing PPi concen-
trations to wild-type RT and the Q151E mutant in the pres-
ence of dCTP, AZTTP, and efavirenz. As shown in Fig. 3B and
Table 4, the phosphorolytic activity of wild-type RT was com-
pletely inhibited by efavirenz, as expected from the data shown
in Table 3. On the other hand, efavirenz did not affect the
ability of the Q151E mutant to remove the chain-terminating
AZTMP residue (Fig. 3D and Table 4).
Effects of the Q151E mutation on the phosphorolytic re-
moval of d4TMP by HIV-1 RT and its inhibition by efavirenz.
The results presented above revealed a difference between
wild-type RT and the Q151E mutant in both phosphorolytic
activity and sensitivity to efavirenz in the presence of AZTTP.
In order to investigate whether this difference was dependent
on the particular NRTI studied, we performed similar studies
with the active form of another clinically approved thymidine
analog, d4TTP (stavudine triphosphate). The phosphorolytic
activities of wild-type RT and the Q151E mutant were then
tested with the d24-d66-mer template in the presence of dCTP
and d4TTP. As shown in Fig. 4A and C, both enzymes were
able to phosphorolytically remove a d4TMP residue from the
chain-terminated primer in response to increasing PPi concen-
trations, with comparable catalytic efficiencies (Table 4). When
efavirenz was added together with PPi, a strong inhibition of
the phosphorolytic activity of the wild-type enzyme was ob-
served (Fig. 4B and Table 4), whereas the Q151E mutant was
unaffected (Fig. 4D and Table 4).
DISCUSSION
As shown in Fig. 1, the residues which were the subject of
the present study, namely, D113, Y115, F116, Q151, and M184,
are part of the dNTP-binding pocket of HIV-1 RT (7). As
revealed by the structure of a ternary complex of HIV-1 RT,
double-stranded DNA, and a bound dTTP (8), the D113 res-
idue helps to coordinate the triphosphate moiety of the incom-
ing nucleotide together with R72. The R72 side chain is stabi-
lized by a hydrogen bond with Q151. The side chains of D113,
Y115, F116, and Q151 also contribute to form a small pocket
which accommodates the 3-OH of the incoming nucleotide.
The 2 and 3 positions of the sugar moiety of the incoming
nucleotide are thus flanked on one side by the Y115 aromatic
side chain and on the other side by the Q151 side chain.
Earlier biochemical studies already addressed the functional
roles of these residues in the polymerization reaction as well as
in drug resistance against NRTIs (7, 27). For example, the
D113 residue has been proposed to be equivalent to E710 of
the Klenow fragment, which is essential for enzymatic activity.
The Y115 side chain, on the other hand, was shown to act
mainly as a sensor for the 2-ribose position and to help to
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stabilize binding of the incoming dNTP and discriminate be-
tween ribo- and deoxyribose moieties.
We chose to analyze this set of mutations based on their
involvement in the dNTP binding and incorporation steps of
the RT catalytic cycle and their role in establishing NRTI
resistance. In fact, mutations at these positions have been
shown to confer resistance to NRTIs, although the exact mech-
anism of resistance has not been elucidated in all cases. The
best-characterized mutations are those at codon 184, which
have been shown to give specific resistance to the drug lami-
vudine, and substitutions at position 151, which, when present
together with the F116Y mutation, result in a multidrug-resis-
tant phenotype (9). Amino acid substitutions at positions 113
and 115 have also been observed in clinical HIV-1 isolates, but
at a low rate and always associated with other NRTI mutations.
The aim of this study was to investigate the correlation
among the effects induced by these mutations on different bio-
chemical properties of HIV-1 RT, in particular its PPi-dependent
primer unblocking activity and its sensitivity to NNRTIs.
The results presented here indicate that some mutations can
have profound effects on some NRTIs while hardly affecting
other ones. For example, the Y115F and Q151E/N mutations
showed the highest levels of resistance to AZT, but when the
same mutants were tested in the presence of d4TTP, only the
Q151E and Q151N mutants showed significant resistance
(15.6- and 3.5-fold, respectively) to inhibition, whereas the
Y115F mutant retained a sensitivity comparable to that of the
wild-type enzyme. In light of the preferential interaction of
Y115 with the 2 position of the sugar ring, as suggested by
structural data (4), it is possible that the lack of the 2 hydrogen
in the 2,3-didehydro sugar ring of d4T renders this nucleotide
analog less sensitive to modifications at position 115. On the other
hand, the interaction between Q151 and the thymidine base of
AZTMP, as revealed in the structure (20), might also be main-
tained with the thymidine analog d4T, thus explaining the similar
resistance of the Q151E and Q151N mutants to both analogs.
The results presented here also indicate that single amino
acid substitutions within the dNTP-binding pocket can differ-
entially affect the viral RT phosphorolytic activity. For exam-
ple, the D113E mutation caused a reduction in the enzyme’s
sensitivity to PPi inhibition when a normal 3 dNTP (dTTP)
was used as a substrate but failed to confer significant resis-
tance to AZTTP. On the other hand, the Y115F mutant
showed a PPi sensitivity similar to that of the wild-type enzyme
but was strongly resistant to AZTTP inhibition. Since D113 has
been implicated in an interaction with the triphosphate moiety
of the nucleotide (8), whereas Y115 contacts mainly the sugar
(4), it is reasonable that a mutation in the latter position will
scarcely influence the binding of PPi.
The Q151E mutation caused a 3.7-fold increase in the Ki
value for PPi with respect to that of wild-type RT. Structural
studies have suggested that after bond formation between the
3-OH of the primer and the 
-phosphate, the release of the
,-phosphate of the dNTP as PPi may involve residues K65
and R72 (8). The latter residue forms a hydrogen bond with
Q151. Thus, the nonconservative substitution Q151E likely
destabilizes this bond and reduces PPi binding. An additional
effect of this mutation may be an increase in the net negative
charge of the binding pocket. In fact, during polymerization, a
substantial amount of negative charge proximal to the active
site comes from the side chains of the three catalytic carboxy-
lates (D110, D185, and D186), the three phosphates of the
incoming dNTP, and to a lesser extent, the nucleophilic 3-OH
of the primer terminus and the carboxylate of D113. Two metal
ions (Mg2), which are essential for catalysis, help to shield the
resulting repulsive forces. However, crystal structures of a
polymerase stalled at a chain-terminated primer showed only
one bound metal ion (8). Thus, the addition of a glutamic acid
at position 151 will increase the repulsion between the nega-
tively charged PPi and the other electronegative species in the
vicinity of the active site.
Both the Q151E and Q151N mutants showed reduced PPi
binding and phosphorolytic rates with respect to wild-type RT
when AZTMP was the chain-terminating nucleotide. The
Q151E mutant was again the most affected mutant, with an
overall 20-fold lower efficiency (kcat/Kd value) of PPi-mediated
AZTMP removal than that of wild-type RT. However, when
the same analysis was performed in the presence of d4TTP, the
overall efficiency of d4TMP removal by the Q151E mutant was
comparable to that of the wild-type enzyme. This suggests that
the efficiency of the pyrophosphorolytic reaction is influenced
by the nature of the terminating residue. The observation that
wild-type RT was fourfold more efficient at removing AZTMP
than d4TMP further supports this notion.
Finally, the ability of NNRTIs to synergistically interact with
NRTIs through inhibition of the primer unblocking activity of
the viral RT can be challenged by NRTI resistance mutations,
even in the absence of detectable effects on NNRTI binding to
the enzyme. In fact, our studies showed that efavirenz effi-
ciently inhibited the pyrophosphorolytic removal of AZTMP
FIG. 4. PPi-dependent removal of a chain-terminating d4TMP res-
idue by wild-type HIV-1 RT and the Q151E mutant and its inhibition
by efavirenz. (A) Reactions were carried out as described in Materials
and Methods, with 40 nM wild-type RT, 2 M dCTP, and 0.2 M
d4TTP and in the absence (lane 1) or presence (lanes 2 to 7) of
increasing amounts of PPi. M, 5-labeled 24-mer oligonucleotide
marker. The template sequence is shown on the right side of the panel.
The removal of AZTMP is indicated by a decrease in 2 products
which is dependent on the PPi concentration. (B) Same conditions as
those for panel A, but with the presence of 0.3 M efavirenz in lanes
2 to 7. (C) Reactions were carried out as described in Materials and
Methods, with 60 nM Q151E RT, 2 M dCTP, and 2 M d4TTP and
in the absence (lane 1) or presence (lanes 2 to 7) of increasing amounts
of PPi. M, 5-labeled 24-mer oligonucleotide marker. The template
sequence is shown on the right side of the panel. The removal of
AZTMP is indicated by a decrease in 2 products which is dependent
on the PPi concentration. (D) Same conditions as those for panel B,
but with the presence of 0.3 M efavirenz in lanes 2 to 7.
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and d4TMP by wild-type RT but not by the Q151E mutant.
However, this lack of efavirenz inhibition was not due to
weaker binding of the Q151E mutant to efavirenz. Thus, the
efficiency of pyrophosphorolysis by the Q151E mutant was
dependent on the nature of the chain-terminating residue, but
its refractiveness to efavirenz inhibition was not.
NNRTIs bind to a critical hinge region involved in the rel-
ative motions of the RT finger and thumb subdomains, either
altering or blocking these movements (1, 12, 26). Thus, these
compounds modify the conformation of the catalytic site so
that the crucial Mg2 ions are no longer present in the proper
alignment with the carboxyl groups for efficient catalysis. Since
our results showed that the Q151E and Q151N mutants were
already impaired in nucleotide binding and catalysis as well as
in pyrophosphorolytic activity, it is possible that the distortion
of the active site imposed by these mutations also alters the
enzyme’s response to efavirenz. Indeed, the polymerase activ-
ities of the Q151E and Q151N mutants were found to be
slightly hypersensitive to efavirenz inhibition.
In conclusion, even though different mutations within the
dNTP-binding pocket of HIV-1 RT can result in a common
phenotype (i.e., NRTI resistance), the molecular mechanisms
underlying this phenotype can be very different. Moreover, the
same mutation can give rise to different phenotypes depending
on the microenvironmental conditions and the nature of the
substrates and/or inhibitors.
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